Two synthetic peptides investigated for their potential to improve weight control are AOD9604 and Semaglutide. A peptide fragment is an extract of growth hormone known as AOD9604. The prevailing belief is that it may promote weight reduction by increasing fat oxidation and triggering the breakdown of fat cells. Semaglutide has been hypothesized to control hunger and blood sugar levels by acting similarly to the hormone GLP-1. Experimental studies have suggested substantial weight reduction outcomes.
Despite their similarities, the processes by which these two peptides may exert their effects have been theorized to be quite distinct. Additionally, their study is progressing at various levels. Take a look at this comparison between AOD9604 and Semaglutide.
GLP-1: Semaglutide
There are two naturally-produced incretin hormones, GLP-1 (glucagon-like peptide 1) and GIP (gastric inhibitory peptide). Both are considered to encompass intestinal production, binding sites, and vagal nerve and brain receptors. Two synthetic GLP-1 agonists are Semaglutide and Liraglutide. They have been speculated to act similarly to GLP-1 by binding to the GLP-1 receptor.
Studies suggest that Semaglutide may stimulate the pancreas to secrete and produce more insulin. This is the initial rationale for the peptide’s development and evaluation in diabetic research. According to studies, it is the first chemical that appears to target the root cause of diabetes by improving beta cell survival and multiplication. In addition to a 1% drop in A1c levels (a marker of long-term blood sugar levels), it seems to reduce all-cause mortality. Investigations purport it may enhance insulin secretion by up to ten compared to the initial level.
Findings imply that Semaglutide may significantly reduce the desire to eat by making the brain feel full. According to the researchers, this may potentially be the primary mechanism by which Semaglutide might cause weight reduction. In one study, the peptide’s impact in research models was evaluated over a 20-week course, with the average rate of weight dropping 8% without any adjustments in control settings like physical activity and food. Under adjusted conditions, the research models reportedly dropped 16% of their body weight under exposure to Semaglutide.
AOD9604 Peptide
The complicated management of body composition, including weight and fat metabolism, is considered to be facilitated by growth hormone (GH). There are four main ways in which growth hormone (GH) may affect weight management: regulation of hunger, insulin sensitivity, fat metabolism, and muscular development. Similarities between these GH characteristics and those of the incretins, such as GLP-1, that were mentioned before may already be apparent to the astute reader.
By increasing insulin sensitivity, GH may facilitate glucose absorption by muscle cells and inhibits the conversion of glucose to fat. This makes perfect sense, given that GH may promote the development of new muscles and bones and appears to act to increase protein synthesis. Thanks to these features, GH is a powerful hormone that may promote the growth of lean body mass.
Data also suggests that GH may enhance lipolysis by blocking lipoprotein lipase and activating hormone-sensitive lipase (HSL), two enzymes considered to be involved in the breakdown of stored fat. Due to this, adipose tissue (fat tissue) may become more prone to breakdown than synthesis. This will be discussed more in depth further on.
The “lipolytic fragment” moniker for AOD9604 comes from the fact that this GH fragment has been hypothesized by researchers to promote fat metabolism. It turns out that the various receptor-binding capacities of the GH peptide’s various segments may explain why these segments perform distinct roles. Many larger compounds may possess several binding domains and serve various purposes.
By focusing on a specific region of the GH molecule, rather than influencing insulin resistance, insulin-like growth factor-1 levels, or the development of muscle or bone, AOD9604 seems only to promote fat burning.
Based on mouse studies, AOD9604 has been hypothesized to have the potential to increase weight reduction by a factor of three compared to a placebo. On the other hand, there have been some contradicting clinical studies. While AOD9604 did appear to result in weight reduction in one study when no adjustments were made to the diet, it seemed to have no effect when paired with a low-calorie diet and systematic exercise in another trial.
A possible explanation for the disparity in these findings might lie in the operation of AOD9604. As suggested by mouse studies, it seems to attach to beta(3)-adrenergic receptors, which might vary greatly depending on many things. AOD9604 has been theorized to enhance fat burning by increasing levels of this receptor in obese mice. The beta(3)-adrenergic receptors appear unaffected by AOD9604 in lean mice. To understand why these two clinical studies had different findings, further exploration is needed to determine whether these very varied receptors are also affected by food choices and activity.
Changes in hunger are the last mechanism via which GH may potentially induce weight loss. However, this becomes much more complicated when GH is a factor as it may potentially increase hunger, but apparently only in cases of certain low-fat and high-sugar diets. How can a peptide have the dual effect of increasing and decreasing hunger?
According to studies, GH may act to regulate ghrelin release, stimulate insulin-like growth factor-1 secretion, bind to GH in the brain, and indirectly may stimulate fat breakdown, among at least four other actions. When considering AOD9604, this second purported GH impact is crucial.
Adipose tissue is the principal source of the hunger hormone leptin. Essentially, it signals to the organism eating is not required since fat is not being broken down. It follows that AOD9604’s potential to break down fat should increase hunger. Yes, fatty tissue does secrete hormones, but leptin is not the only nor the strongest of them.
Buy AOD-9604 if you are a scientist interested in further studying the potential of this peptide in experimental studies. Please note that none of the substances mentioned in this article have been approved for human consumption and should, therefore, not be used by unlicensed professionals or academics outside of contained laboratory settings. This paper serves educational purposes only.
